Arvinas (ARVN) Competitors $7.79 -0.10 (-1.27%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.78 0.00 (-0.06%) As of 07/11/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. APLS, NAMS, TWST, DNLI, KNSA, AGIO, RXRX, CGON, VCEL, and BEAMShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Vericel (VCEL), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals CG Oncology Vericel Beam Therapeutics Arvinas (NASDAQ:ARVN) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Does the media refer more to ARVN or APLS? In the previous week, Arvinas had 2 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 6 mentions for Arvinas and 4 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.93 beat Arvinas' score of 0.43 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apellis Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ARVN or APLS? 95.2% of Arvinas shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, ARVN or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.16-$198.90M-$0.66-11.80Apellis Pharmaceuticals$781.37M3.13-$197.88M-$1.79-10.86 Which has more risk & volatility, ARVN or APLS? Arvinas has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Do analysts rate ARVN or APLS? Arvinas currently has a consensus target price of $20.29, indicating a potential upside of 160.46%. Apellis Pharmaceuticals has a consensus target price of $39.79, indicating a potential upside of 104.68%. Given Arvinas' higher possible upside, research analysts plainly believe Arvinas is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Is ARVN or APLS more profitable? Arvinas has a net margin of -10.92% compared to Apellis Pharmaceuticals' net margin of -28.83%. Arvinas' return on equity of -7.74% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-10.92% -7.74% -4.11% Apellis Pharmaceuticals -28.83%-99.19%-25.35% SummaryApellis Pharmaceuticals beats Arvinas on 9 of the 17 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$568.59M$2.94B$5.55B$9.09BDividend YieldN/A2.45%5.07%4.03%P/E Ratio-11.8020.8528.2520.32Price / Sales2.16291.87431.56110.05Price / CashN/A41.0526.2427.98Price / Book0.957.638.125.50Net Income-$198.90M-$55.05M$3.19B$250.38M7 Day PerformanceN/A7.11%3.68%2.19%1 Month Performance5.41%8.14%7.70%10.92%1 Year Performance-73.02%1.62%29.39%16.41% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.916 of 5 stars$7.79-1.3%$20.29+160.5%-73.0%$568.59M$263.40M-11.80420APLSApellis Pharmaceuticals4.1815 of 5 stars$17.42-4.6%$39.79+128.4%-50.8%$2.19B$781.37M-9.73770NAMSNewAmsterdam Pharma2.7164 of 5 stars$19.46-2.0%$42.89+120.4%+8.4%$2.18B$45.56M-10.354TWSTTwist Bioscience4.3777 of 5 stars$35.59-6.8%$50.40+41.6%-28.8%$2.13B$312.97M-10.95990Gap DownDNLIDenali Therapeutics4.6397 of 5 stars$14.25-3.0%$33.71+136.6%-36.5%$2.07B$330.53M-5.34430News CoverageInsider TradeAnalyst RevisionKNSAKiniksa Pharmaceuticals International3.3912 of 5 stars$27.95+0.3%$38.80+38.8%+32.4%$2.04B$481.17M-111.80220AGIOAgios Pharmaceuticals4.3481 of 5 stars$35.21-2.4%$58.60+66.4%-14.9%$2.04B$36.50M3.13390News CoverageInsider TradeAnalyst RevisionRXRXRecursion Pharmaceuticals1.9894 of 5 stars$4.93-6.5%$7.00+42.0%-36.8%$2.00B$59.82M-2.79400Analyst ForecastOptions VolumeGap DownHigh Trading VolumeCGONCG Oncology2.4367 of 5 stars$26.25-2.4%$58.67+123.5%-24.5%$2.00B$662K-17.3861Positive NewsAnalyst UpgradeVCELVericel3.7797 of 5 stars$39.41-5.6%$61.14+55.1%-17.7%$1.98B$237.22M1,314.10300Positive NewsBEAMBeam Therapeutics2.1047 of 5 stars$19.18-4.1%$48.75+154.2%-21.3%$1.93B$63.52M-4.16510News Coverage Related Companies and Tools Related Companies APLS Competitors NAMS Competitors TWST Competitors DNLI Competitors KNSA Competitors AGIO Competitors RXRX Competitors CGON Competitors VCEL Competitors BEAM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts